Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 507

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 507
---
 calculation of diluted loss per share in loss periods as their effect would be anti-dilutive. For the six months ended June 30, 2025 and 2024, the total number of share options, warrants and convertible notes excluded from the calculation of diluted earnings per share due to their anti-dilutive nature, are and , respectively.

18. COMMITMENTS AND CONTINGENCIES

Contingent payment obligation

As of June 30, 2025, the Group does not have any non-cancellable purchase commitments.

The Group has contingency payment obligations under each of the license agreements, such as milestone payments, royalties, research and development funding, if certain condition or milestone is met.

Milestone payments are to be made upon achievements of certain conditions, such as Investigational New Drugs (“IND”) filing or U.S. Food and Drug Administration (“FDA”) approval, first commercial sale of the licensed products, or other achievements.

|                                                        |     | Amount     |           |
|                                                        |     | -unaudited |           |
| Drug molecules: up to the conditions and milestones of |     |            |           |
| From entering phase 1 to before first commercial sale  |     |            |   920,000 |
| First commercial sale                                  |     |            |   800,000 |
| Net sales amount more than certain threshold in a year |     |            | 7,000,000 |
| Subtotal                                               |     | $          | 8,720,000 |

For the six months ended June 30, 2025 and 2024, the Group incurred $nil and $ milestone payments respectively. For the six months ended June 30, 2025 and 2024, the Group did not incur any royalties or research and development funding.

Legal proceedings

The Group is party to a lawsuit initially filed on notice on September3, 2024, by Karen Cheung (“Plaintiff”) in the Supreme Court of the State of New York, County of New York (“State Court Action”) (Index No. 654541/2024), which sought relief arising from (i) violations of the federal Racketeer Influenced and Corrupt Organizations Act

F-49 APTORUM GROUP LIMITED NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Stated in U.S. Dollars) 18. COMMITMENTS AND CONTINGENCIES (cont.) (“RICO”), 18 § U.S.C. 1961(c